NeXstar Pharmaceuticals Inc., of Boulder, Colo., and BectonDickinson and Co., of Franklin Lakes, N.J., redefined terms of theiragreement related to in vitro diagnostic reagents using NeXstar'sSELEX combinatorial chemistry process. The deal allows NeXstar topursue diagnostic application's outside Becton Dickinson's focusarea.

Diatech Inc., of Londonderry, N.H., bought rights to a patent andrelated properties owned by Receptor Laboratories Inc., of Chicago.The technology allows for the identification of small peptides thatbind tightly to specific proteins involved in disease states.

Amdex A/S, of Copenhagen, Denmark, signed a license agreementwith Amersham International plc, of Little Chalfont, U.K., coveringthe use of Amdex conjugate technology in the Amersham range ofBiotrak cellular communication immunoassays.

BioResearch Ireland, of Dublin, and Raggio-Italgene, of Pomezia,Italy, signed a letter of intent to develop DNA-probe assays.

(c) 1997 American Health Consultants. All rights reserved.